MedAvail (NASDAQ: MDVL) is one of 778 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare MedAvail to similar companies based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, risk and dividends.
Earnings & Valuation
This table compares MedAvail and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MedAvail||$1.03 million||-$4.26 million||-2.55|
|MedAvail Competitors||$1.89 billion||$219.07 million||-6.34|
MedAvail’s rivals have higher revenue and earnings than MedAvail. MedAvail is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent ratings for MedAvail and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Pharmaceutical preparations” companies have a potential upside of 20.44%. Given MedAvail’s rivals higher possible upside, analysts clearly believe MedAvail has less favorable growth aspects than its rivals.
This table compares MedAvail and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
MedAvail has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, MedAvail’s rivals have a beta of 0.40, meaning that their average share price is 60% less volatile than the S&P 500.
Insider and Institutional Ownership
40.2% of MedAvail shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 45.3% of MedAvail shares are held by insiders. Comparatively, 15.4% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MedAvail beats its rivals on 7 of the 13 factors compared.
MedAvail Company Profile
MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississauga, Canada.
Receive News & Ratings for MedAvail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedAvail and related companies with MarketBeat.com's FREE daily email newsletter.